Characterization of Pharmacokinetic Profiles and Metabolic Pathways of 20(S)-Ginsenoside Rh1 in vivo and in vitro

 

 Buy Article Permissions and Reprints

Abstract

20(S)-Ginsenoside Rh1 is one of the important protopanaxatriol ginsenosides and has been reported to be the main hydrolysis product reaching the systemic circulation after oral ingestion of ginseng. However, its pharmacokinetic characteristics and metabolic fate have never been reported. The present study was therefore designed to elucidate its pharmacokinetic profiles and metabolic pathways both in vivo and in vitro. The absolute bioavailability of 20(S)-ginsenoside Rh1 in rats was only 1.01 %. Identification of metabolites showed that, after intragastrical administration of ginsenoside Rh1, two mono-oxygenated metabolites were detected from the urine, bile, liver tissue, and intestinal tract content, while the de-glucosylated product, 20(S)-protopanaxatriol, was only found in the contents of the intestinal tract. An in vitro incubation study confirmed that the CYP450-catalyzed mono-oxygenation, the intestinal bacteria mediated de-glucosylation, and the gastric acid mediated hydration reaction were the main metabolic pathways of 20(S)-ginsenoside Rh1. The presystemic metabolism as evidenced from this study may partially explain its poor bioavailability.

References

• 1 Shibata S. Chemistry and cancer preventing activities of ginseng saponins and some related triterpenoid compounds.  J Korean Med Sci. 2001;  16 (Suppl.) S28-S37
  PubMedGoogle Scholar
• 2 Park E K, Choo M K, Han M J, Kim D H. Ginsenoside Rh1 possesses antiallergic and anti-inflammatory activities.  Int Arch Allergy Immunol. 2004;  133 113-120
  CrossrefPubMedGoogle Scholar
• 3 Wang Y, Wang B X, Liu T H, Minami M, Nagata T, Ikejima T. Metabolism of ginsenoside Rg1 by intestinal bacteria. II. Immunological activity of ginsenoside Rg1 and Rh1.  Acta Pharmacol Sin. 2000;  21 792-796
  PubMedGoogle Scholar
• 4 Hasegawa H. Proof of the mysterious efficacy of ginseng: basic and clinical trials: metabolic activation of ginsenoside: deglycosylation by intestinal bacteria and esterification with fatty acid.  J Pharmacol Sci. 2004;  95 153-157
  CrossrefPubMedGoogle Scholar
• 5 Wang Y, Liu T H, Wang W, Wang B X. Research on the transformation of ginsenoside Rg1 by intestinal flora.  China J Chin Mater Med. 2001;  26 188-190
  PubMedGoogle Scholar
• 6 Chang Y W, Yao H T, Chien D S, Yeh T K. High-performance liquid chromatography-electrospray mass spectrometry for the simultaneous determination of multiple active components in Sheng-Mai San, a prescription of traditional Chinese medicine.  Phytochem Anal. 2008;  19 258-265
  CrossrefPubMedGoogle Scholar
• 7 Zhu D, Li Z, Yan Y, Zhu J. A research on chemical dynamic changes and drug efficacy of shengmaisan compound prescription: chemical researches on shengmaisan prescription (II).  China J Chin Mater Med. 1998;  23 291-293 319-320
  PubMedGoogle Scholar
• 8 Tawab M A, Bahr U, Karas M, Wurglics M, Schubert-Zsilavecz M. Degradation of ginsenosides in humans after oral administration.  Drug Metab Dispos. 2003;  31 1065-1071
  CrossrefPubMedGoogle Scholar
• 9 Cai Z W, Qian T X, Wong R NS, Jiang Z H. Liquid chromatography-electrospray ionization mass spectrometry for metabolism and pharmacokinetic studies of ginsenoside Rg3.  Anal Chim Acta. 2003;  492 283-293
  CrossrefPubMedGoogle Scholar
• 10 Han B H, Park M H, Han Y N, Woo L K, Sankawa U, Yahara S, Tanaka O. Degradation of ginseng saponins under mild acidic conditions.  Planta Med. 1982;  44 146-149
  Article in Thieme ConnectPubMedGoogle Scholar
• 11 Zhang X, Song F, Cui M, Liu Z, Liu S. Investigation of the hydrolysis of ginsenosides by high performance liquid chromatography-electrospray ionization mass spectrometry.  Planta Med. 2007;  73 1225-1229
  Article in Thieme ConnectPubMedGoogle Scholar
• 12 Qian T, Cai Z, Wong R N, Mak N K, Jiang Z H. In vivo rat metabolism and pharmacokinetic studies of ginsenoside Rg3.  J Chromatogr B Analyt Technol Biomed Life Sci. 2005;  816 223-232
  CrossrefPubMedGoogle Scholar
• 13 Hao H, Wang G, Cui N, Li J, Xie L, Ding Z. Identification of a novel intestinal first pass metabolic pathway: NQO1 mediated quinone reduction and subsequent glucuronidation.  Curr Drug Metab. 2007;  8 137-149
  CrossrefPubMedGoogle Scholar
• 14 Von Bahr C, Groth C G, Jansson H, Lundgren G, Lind M, Glaumann H. Drug metabolism in human liver in vitro: establishment of a human liver bank.  Clin Pharmacol Ther. 1980;  27 711-725
  PubMedGoogle Scholar
• 15 Sun J, Wang G, Xie H T, Li H, Pan G Y, Tucker I. Simultaneous rapid quantification of ginsenoside Rg1 and its secondary glycoside Rh1 and aglycone protopanaxatriol in rat plasma by liquid chromatography-mass spectrometry after solid-phase extraction.  J Pharm Biomed Anal. 2005;  38 126-132
  PubMedGoogle Scholar
• 16 Li X, Sun J G, Wang G J, Hao H P, Liang Y, Zheng Y, Yan B, Sheng L. Simultaneous determination of panax notoginsenoside R1, ginsenoside Rg1, Rd, Re and Rb1 in rat plasma by HPLC/ESI/MS: platform for the pharmacokinetic evaluation of total panax notoginsenoside, a typical kind of multiple constituent traditional Chinese medicine.  Biomed Chromatogr. 2007;  21 735-746
  CrossrefPubMedGoogle Scholar
• 17 Li X, Wang G J, Sun J G, Hao H P, Xiong Y, Yan B, Zheng Y, Sheng L. Pharmacokinetic and absolute bioavailability study of total panax notoginsenoside, a typical multiple constituent traditional chinese medicine (TCM) in rats.  Biol Pharm Bull. 2007;  30 847-851
  CrossrefPubMedGoogle Scholar
• 18 Kasai R, Hara K, Dokan R, Suzuki N, Mizutare T, Yoshihara S, Yamasaki K. Major metabolites of ginseng sapogenins formed by rat liver microsomes.  Chem Pharm Bull (Tokyo). 2000;  48 1226-1227
  PubMedGoogle Scholar
• 19 Hasegawa H, Suzuki R, Nagaoka T, Tezuka Y, Kadota S, Saiki I. Prevention of growth and metastasis of murine melanoma through enhanced natural-killer cytotoxicity by fatty acid-conjugate of protopanaxatriol.  Biol Pharm Bull. 2002;  25 861-866
  CrossrefPubMedGoogle Scholar

Prof. Dr. Guangji Wang

Key Lab of Drug Metabolism and Pharmacokinetics
China Pharmaceutical University

24 Tong jia xiang street Mail Box 210

Nanjing 210009

People's Republic of China

Phone: + 86 25 83 27 11 28

Fax: + 86 25 85 30 67 50

Email: guangjiwang@hotmail.com

Dr. Haiping Hao

Key Lab of Drug Metabolism and Pharmacokinetics
China Pharmaceutical University

24 Tong jia xiang street Mail Box 210

Nanjing 210009

People's Republic of China

Phone: + 86 25 85 39 10 89

Fax: + 86 25 85 30 67 50

Email: hhp_770505@yahoo.com.cn

• Supplementary Material